EcoDrugPlus

C-X-C Motif Chemokine Receptor 4

Ensembl ID : ENSMAMG00000017149
Gene Symbol: CXCR4
4 Cross references
201 Possible Orthologues:

C-Reactive Protein-Like

Ensembl ID : ENSMAMG00000011157
Gene Symbol: LOC113136296
2 Cross references
408 Possible Orthologues:

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSMAMG00000022871
Gene Symbol: CFTR
3 Cross references
214 Possible Orthologues:

Dna (Cytosine-5-)-Methyltransferase 1

Ensembl ID : ENSMAMG00000012342
Gene Symbol: DNMT1
3 Cross references
210 Possible Orthologues:

Dna Topoisomerase I

Ensembl ID : ENSMAMG00000010464
Gene Symbol: TOP1
3 Cross references
198 Possible Orthologues:

Dna Topoisomerase I, Like

Ensembl ID : ENSMAMG00000021024
Gene Symbol: TOP1L
3 Cross references
207 Possible Orthologues:

Dna Topoisomerase Ii Beta

Ensembl ID : ENSMAMG00000001653
Gene Symbol: TOP2B
2 Cross references
3 Possible Orthologues:

Emap Like 4

Ensembl ID : ENSMAMG00000022431
Gene Symbol: EML4
3 Cross references
207 Possible Orthologues:

Eph Receptor A3

Ensembl ID : ENSMAMG00000018295
Gene Symbol: EPHA3
3 Cross references
210 Possible Orthologues:

Fau Ubiquitin Like And Ribosomal Protein S30 Fusion A

Ensembl ID : ENSMAMG00000013349
Gene Symbol: FAUA
3 Cross references
300 Possible Orthologues:

Fyn Proto-Oncogene, Src Family Tyrosine Kinase A

Ensembl ID : ENSMAMG00000005399
Gene Symbol: FYNA
3 Cross references
191 Possible Orthologues:

Fyn Proto-Oncogene, Src Family Tyrosine Kinase B

Ensembl ID : ENSMAMG00000004025
Gene Symbol: FYNB
3 Cross references
196 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).